Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.9 million.

  • Rhythm Pharmaceuticals' Consolidated Net Income fell 2122.55% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 2572.22%. This contributed to the annual value of -$260.6 million for FY2024, which is 4111.16% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$52.9 million for Q3 2025, which was down 2122.55% from -$46.6 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Consolidated Net Income high stood at $43.8 million for Q1 2021, and its period low was -$141.4 million during Q1 2024.
  • For the 5-year period, Rhythm Pharmaceuticals' Consolidated Net Income averaged around -$44.9 million, with its median value being -$44.2 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 22805.88% in 2021, then crashed by 22007.09% in 2022.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Consolidated Net Income stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then fell by 3.98% to -$43.3 million in 2024, then decreased by 22.2% to -$52.9 million in 2025.
  • Its Consolidated Net Income was -$52.9 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$49.5 million in Q1 2025.